Closed-loop control strategy for type I diabetic patients

Abstract

Administering ‘optimal’ amount of insulin to maintain the blood glucose (BG) concentration in the normoglycaemic range is vital in type I diabetics. Insulin injection therapy is widely practiced for the maintenance of blood glucose levels within the normoglycemic range (70–100 mg/dL) for type I diabetics. Current insulin therapy for patients with type I diabetes often results in high variability in blood glucose concentrations and may cause hyperglycemic/hypoglycemic episodes. Closing the glucose control loop with a fully automated electro-mechanical pancreas will improve the quality of life for insulin-dependent patients. The performances of the nominal continuous H∞ controller and robust controllers are compared with the proportional-integral-derivative (PID) and internal model control (IMC) controllers. The resulting PID and IMC controllers are designed by considering first order plus delay time (FOPDT) model of the system to be controlled.